Carlos Gil Ferreira completed his training in Medical Oncology at the National Cancer Institute (INCA), in Rio de Janeiro in 1997. In the same year, he began a doctoral program in Experimental Oncology of the Department of Medical Oncology at the Vrije Universiteit Medical Center ( VUMC) in Amsterdam. In VUMC, Dr. Ferreira also worked for 4 years as a fellow in clinical and translational research. Since 2001, Dr. Ferreira back in Brazil working at the National Cancer Institute, where he was appointed Head of the Clinical and Translational Service in 2002. In 2004, created the National Tumor Bank and DNA INCA. In 2010 Dr. Ferreira launched the New Development program INCA Medicines and the National Network of Clinical Research in Oncology linked to the Ministry of Health. His main interests are lung cancer, molecular diagnosis and development of new anticancer drugs and biomarkers. In addition, Dr. Ferreira's lead author and co-author of more than 120 reviewed articles and book chapters. Between 2015 and 2018 he was Corporate Director of Oncology D'or, Neotropical Group Coordinator Oncology and Research Coordinator in Oncology Institute of Research and Higher Education (IDOR) Dr. Ferreira serves also as the co-chair of the IASLC Fellowship Committee, member of the AACR International Affairs Committee and board member of the Americas Health Foundation (AHF). From March 2018, began acting as President of the Oncoclinicas Institute and Director of the Oncoclinica Group.